Meihua International Medical Technologies, Fly-E Group, and Other Major Stocks Decline in Pre-Market Trading on Monday

Written by Emily J. Thompson, Senior Investment Analyst

PRTC+1.81%

VCYT+0.68%

FLYE-5.16%

Source: Benzinga

Updated: Dec 08 2025

0mins

Source: Benzinga

U.S. Stock Futures: U.S. stock futures showed mixed results, with Dow futures down approximately 0.1% on Monday morning.
Meihua International Medical Technologies: Shares of Meihua International Medical Technologies fell 32.9% in pre-market trading after the announcement of its delisting from Nasdaq.
Other Notable Stock Movements: Several other stocks experienced significant declines in pre-market trading, including SMX down 17.2%, Gulf Resources down 16.1%, and Wheeler Real Estate down 16.1%.
Market Reactions: The market saw various stocks decline after previous gains, with Fly-E Group and Ecarx Holdings also reporting notable drops due to regulatory issues and market fluctuations.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like PRTC with instant alerts to capture every critical market movement.

PRTC

$19.11+Infinity%1D

Analyst Views on PRTC

About PRTC

PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.